Prostate Cancer

Updates on patient eligibility and methods from the INDICATE phase 3 trial were presented at the 2021 American Society of Clinical Oncology annual meeting.

Real-world study suggests prostate-specific antigen levels, race, and the use of androgen deprivation therapy are predictors of a positive FACBC PET/CT scan.

Recent advances in the treatment of mCRPC include immunotherapies, such as sipuleucel-T, the first therapeutic cancer vaccine to receive approval from the US Food and Drug Administration.